AM E3-SG3249, a First-in-Class α-CRLF2 Antibody-Drug Conjugate for the Treatment of CRLF2-Rearranged Ph-like B-ALL

About this poster

This poster presents the preclinical development of AM E3-SG3249, a first-in-class antibody-drug conjugate targeting CRLF2 for the treatment of CRLF2-rearranged Ph-like B-ALL. The compound demonstrates potent cytotoxicity in vitro and significant antitumor activity in xenograft models, with efficacy linked to CRLF2 receptor density. A surrogate ADC enabled further validation and therapeutic window assessment.